http://www.archives-pmr.org/article/PIIS0003999310002352/abstract?rss=yes
Exercise Capacity and Idebenone Intervention in Children and Adolescents
With Friedreich Ataxia
Presented in part to the American College of Sports Medicine, Seattle, WA,
May 28, 2009.
Bart E. Drinkard, MSPTa, Randall E. Keyser, PhDae, Scott M. Paul, MDa, Ross
Arena, PhD, PTf, Jonathan F. Plehn, MDb, Jack A. Yanovski, MD, PhDc,
Nicholas A. Di Prospero, MD, PhDd+
Abstract
Drinkard BE, Keyser RE, Paul SM, Arena R, Plehn JF, Yanovski JA, Di Prospero
NA. Exercise capacity and idebenone intervention in children and adolescents
with Friedreich ataxia.
Objective
To determine the exercise capacity of children and adolescents with
Friedreich's Ataxia (FA) and to evaluate the effects of 6 months of
idebenone treatment on exercise capacity.
Design
Exploratory endpoint in a randomized double-blind, placebo-controlled, phase
II clinical trial designed to investigate the effects of idebenone on a
biomarker of oxidative stress.
Setting
Exercise physiology laboratory in a single clinical research center.
Participants
Ambulatory subjects (N=48; age range, 9–17y) with genetically confirmed FA.
Intervention
Idebenone administered orally 3 times a day for a total daily dose of
approximately 5, 15, and 45mg/kg or matching placebo for 6 months.
Main Outcome Measures
Peak oxygen consumption per unit time (peak VO2) and peak work rate (WR)
were measured during incremental exercise testing at baseline and after
treatment. Echocardiography and neurologic assessments were also completed
before and after treatment.
Results
Baseline mean peak VO2 ± SD was 746±246mL/min (16.2±5.8mL/kg/min), and WR
was 40±23W for all subjects. Peak VO2 and WR were correlated with short
guanine-adenine-adenine allele length and neurologic function. Relative left
ventricular wall thickness was increased but left ventricular ejection
fraction was normal in most subjects; there was no relationship between any
exercise and echocardiographic measures. There were no significant changes
in mean peak VO2 or WR after idebenone treatment at any dose level relative
to placebo.
Conclusions
Exercise capacity in children and adolescents with FA was significantly
impaired. The basis for the impairment appears to be multifactorial and
correlated to the degree of neurologic impairment. Although idebenone has
previously been shown potentially to improve features of FA, idebenone
treatment did not increase exercise capacity relative to placebo.
a Rehabilitation Medicine Department, Hatfield
Clinical Research Center, National Institutes of Health, Bethesda, MD
b Translational Medicine Branch, National Heart, Lung and Blood Institute,
National Institutes of Health, Bethesda, MD
c Unit on Growth and Obesity, National Institute of Child Health and Human
Development, National Institutes of Health, Bethesda, MD
d Neurogenetics Branch, National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Bethesda, MD
e Center for the Study of Chronic Illness and Disability, George Mason
University, Fairfax, VA
f Departments of Internal Medicine, Physiology and Physical Therapy,
Virginia Commonwealth University, Richmond, VA
Reprint requests to Bart E. Drinkard, MSPT, National Institutes of Health,
Building 10 Room 1-1469, 10 Center Dr, Bethesda, MD 20892-1604
Supported by the National Institutes of Health/National Institute of
Neurological Disorders and Stroke/National Heart, Lung, and Blood Institute
intramural research funds.
No commercial party having a direct financial interest in the results of the
research supporting this article has or will confer a benefit on the authors
or on any organization with which the authors are associated.
This trial was registered with ClinicalTrials.gov (NCT00229632).
The opinions and information contained in this article are those of the
authors and do not necessarily reflect those of the National Institutes of
Health, the Department of Health and Human Services, or the United States
Public Health Service.
PII: S0003-9993(10)00235-2
doi:10.1016/j.apmr.2010.04.007
© 2010 American Congress of Rehabilitation Medicine. Published by Elsevier
Inc. All rights reserved.
http://www.jneuroengrehab.com/content/7/1/30
Innovative gait robot for the
repetitive practice of floor walking and stair climbing up and down in
stroke patients
Stefan Hesse , Andreas Waldner and Christopher Tomelleri
Journal of NeuroEngineering and Rehabilitation 2010,
7:30doi:10.1186/1743-0003-7-30
Published: 28 June 2010
Abstract (provisional)
Background
Stair climbing up and down is an essential part of everyday's mobility. To
enable wheelchair-dependent patients the repetitive practice of this task, a
novel gait robot, G-EO-Systems (EO, Lat: I walk), based on the end-effector
principle, has been designed. The trajectories of the foot plates are freely
programmable enabling not only the practice of simulated floor walking but
also stair climbing up and down. The article intended to compare lower limb
muscle activation patterns of hemiparetic subjects during real floor walking
and stairs climbing up, and during the corresponding simulated conditions on
the machine, and secondly to demonstrate gait improvement on single case
after training on the machine.
Methods
The muscle activation pattern of seven lower limb muscles of six hemiparetic
patients during free and simulated walking on the floor and stair climbing
was measured via dynamic electromyography. A non-ambulatory, sub-acute
stroke patient additionally trained on the G-EO-Systems every workday for
five weeks.
Results
The muscle activation patterns were comparable during the real and simulated
conditions, both on the floor and during stair climbing up. Minor
differences, concerning the real and simulated floor walking conditions,
were a delayed (prolonged) onset (duration) of the thigh muscle activation
on the machine across all subjects. Concerning stair climbing conditions,
the shank muscle activation was more phasic and timely correct in selected
patients on the device. The severely affected subject regained walking and
stair climbing ability.
Conclusions
The G-EO-Systems is an interesting new option in gait rehabilitation after
stroke. The lower limb muscle activation patterns were comparable, a
training thus feasible, and the positive case report warrants further
clinical studies.
tp://www3.interscience.wiley.com/journal/123513804/abstract?CRETRY=1&SRETRY=0
Longitudinal tracking of gait
and balance impairments in cerebellar disease
Susanne M. Morton, PhD, PT 1, Ya-Weng Tseng, PhD, PT 2, Kathleen M.
Zackowski, PhD, OTR 3 4 5, Jaclyn R. Daline, PT, DPT 6, Amy J. Bastian, PhD,
PT 3 4 5 *
1Graduate Program in Physical Therapy and Rehabilitation Science, University
of Iowa Carver College of Medicine, Iowa City, Iowa, USA
2Department of Physical Therapy, Temple University, Philadelphia,
Pennsylvania, USA
3Kennedy Krieger Institute, Baltimore, Maryland, USA
4Department of Neurology, Johns Hopkins University School of Medicine,
Baltimore, Maryland, USA
5Department of Physical Medicine and Rehabilitation, Johns Hopkins
University School of Medicine, Baltimore, Maryland, USA
6Program in Physical Therapy, Washington University School of Medicine, St.
Louis, Missouri, USA
email: Amy J. Bastian (bastian@kennedykrieger.org)
*Correspondence to Amy J. Bastian, Kennedy Krieger Institute, 707 N.
Broadway, Room G-04, Baltimore, MD 21205
Potential conflict of interest: Nothing to report.
Funded by:
NIH
(NICHD/NCMRR); Grant Number: grants K01 HD050369, K01 HD049476, K12
HD055931, R01 HD040289
Foundation for Physical Therapy
http://www.plosgenetics.org/article/fetchObjectAttachment.action;jsessionid=6A548BAFE7F2A0DEABA1E6AAFD928738.ambra01?uri=info%3Adoi%2F10.1371%2Fjournal.pgen.1000984&representation=PDF
http://www.orthosupersite.com/view.aspx?rid=65219
Posted on the
ORTHOSuperSite June 4, 2010
Hybrid construct
provides adequate correction of deformity in
patients with neurological scoliosis
Italian orthopaedists
reported a low rate of complications when treating
patients with high-grade neurological
scoliosis using a hybrid construct that combined
lumbar pedicle screws, Universal Clamps (Zimmer) and
thoracic hooks.
“The hybrid construct …
appears safe and effective in the treatment of patients
affected by high-grade scoliosis, providing a good
correction of deformity and reducing operative time,
radiation exposure and blood loss with respect to all-screws
constructs,” Guido La Rosa, MD, Chief of Orthopedic
Unit, Research Institute Pediatric Hospital “Bambino
Gesu,” Rome, Italy, told
Orthopaedics Today Europe in an interview
prior to the presentation of the study at the
EFORT Congress 2010.
Study design
A prospective series of
15 neurological scoliosis patients were treated by La
Rosa and colleagues between 2002 and 2008 with the
hybrid construct. Patients ranged in age from 10 to 17
years, and etiologies were as follows: cerebral palsy in
12 patients, Friedreich’s ataxia in two and Aicardi
Syndrome in one. All patients had a preoperative Cobb
angle greater than 100°, according to the study abstract.
Story
continues below↓
ADVERTISEMENT

Neurological scoliosis with a marked
hypokyphosis treated by means of bilateral all
level lumbar screws plus all level Universal
Clamps thoracic instrumentation. Excellent
coronal correction with an optimal sagittal
contouring.
Images: La Rosa G |
All patients were
treated by posterior access using the hybrid construct
to stabilize each affected level. A secondary posterior
access was used in three patients to strengthen the
effect of the Universal Clamps, adding a concave
costotomy. Skull traction by sling and pelvic
countertraction to control obliquity were performed in
all cases. Pelvic instrumentation provided iliosacral
screw fixation, and two concave rods and one convex were
used in all patients, the investigators wrote in their
abstract.

Passing the tape under the lamina and under
the concave corrective rod. |

Assembling each titanium clamp to the rod.
|

Tensioning of the tape by means of tightening-gun
and tightening of the blocker at the end of
correction. |
Deformity correction

Final assembly of the hybrid construct.
|
The average percentage
of correction was 70% (32°±7°), with an average loss of
correction of 7° occurring during the mean 36-month
follow-up period (range, 12–84 months). Mean operative
time was 4 hours with a mean blood loss of 1800 mL. On
average, six transpedicular screws (range, 4–11), seven
Universal Clamps (range, 5–9) and five thoracic hooks (range,
4–6) were used in the hybrid constructs, according to
the abstract.
“The amount of coronal
correction is excellent and the control of the sagittal
profile seems better than with all-screws assembly,” La
Rosa said. “In conclusion, the overall incidence of
complications has been quite similar to other corrective
procedures — in particular, no neural complications have
been recorded.”
La Rosa G, Giglio G,
Oggiano L. Treatment of neurological scoliosis of
more than 1008 by using a hybrid contstruct (pedicle
screws plus universal clamps). Paper #F484. To be
presented at the EFORT Congress 2010. June 2-5,
2010. Madrid.
http://www.citeulike.org/user/giovanni/article/7255387
Frataxin and
mitochondrial Fe-S cluster biogenesis.
|
RIS |
Export as RIS which can be
imported into most citation managers |
|
BibTeX |
Export as BibTeX which can
be imported into most citation/bibliography managers |
|
PDF |
Export formatted citations
as PDF |
|
RTF |
Export formatted citations
as RTF which can be imported into most word processors |
|
Delicious |
Export in format suitable
for direct import into delicious.com.
(Setup
a permanent sync to delicious)
|
|
Formatted Text |
Export formatted citations
as plain text |
http://www.citeulike.org/user/giovanni/article/7255387
The Journal of biological chemistry (3 June 2010)
Abstract
Friedreich's ataxia is an
inherited neurodegenerative disease caused by frataxin
deficiency. Frataxin is a conserved mitochondrial protein that
plays a role in Fe-S cluster assembly in mitochondria. Fe-S
clusters are modular cofactors that perform essential functions
throughout the cell. They are synthesized by a multi-step and
multi-subunit mitochondrial machinery that includes a scaffold
protein Isu for assembling a protein bound Fe-S cluster
intermediate. Frataxin interacts with Isu, iron, and with the
cysteine desulfurase Nfs1 that supplies sulfide, thus placing it
at the center of mitochondrial Fe-S cluster biosynthesis.
http://www.news-medical.net/news/20100602/Motion-Therapeutics-to-launch-BalanceWear-Stabilizing-Garments-for-MS.aspx
Motion Therapeutics
to launch BalanceWear Stabilizing Garments for MS
2. June 2010 05:53
For those who suffer from balance disorders and loss of mobility,
promising results from a new stabilizing device may help to
reestablish mobility, confidence and independence. This week,
Motion Therapeutics premieres its BalanceWear™ Stabilizing
Garments at the 24th Annual Meeting for the Consortium of
Multiple Sclerosis Centers in San Antonio. The device is worn as
a vest incorporating Balance-Based Torso-Weighting™ (BBTW™),
patented technology providing stability for patients affected by
many forms of balance problems.
“BalanceWear stabilizing devices address directional loss of
balance, improving equilibrium, balance and mobility immediately
upon application”
Current treatment for balance impairment and balance disorders
include aggressive exercise. While recovery time varies
depending on the patient, some require long-term assistance and
years of treatment. By comparison, patients are noticing "same
day" results with the new BalanceWear devices.
"BalanceWear stabilizing devices address directional loss of
balance, improving equilibrium, balance and mobility immediately
upon application," says Cindy Gibson-Horn PT who invented the
BalanceWear stabilizing garments. "Using objective tests and
measures as well as patterns of weighting the torso according to
balance loss, trained professionals can custom fit the garment
and weights exclusive to each patient need."
Gibson-Horn, et al evidence-based research findings have been
published in several medical periodicals including the Journal
of Neurologic Physical Therapy, Archives of Physical Medicine,
and Journal of Neuro-rehabilitation and Neural Repair featuring
functional improvement of patients with ataxia, multiple
sclerosis, and parietal stroke.
Balance-Based Torso-Weighting method was developed to correct
and support balance disorders associated with Multiple Sclerosis
(MS), brain injuries, Parkinson's disease, and stroke as well as
other destabilizing health issues. The BalanceWear stabilizing
devices assist in postural orientation and equilibrium, abnormal
automatic postural control responses, and directional postural
control dysfunction.
SOURCE Motion Therapeutics Inc.
http://www.ncbi.nlm.nih.gov/pubmed/20111601
Flavin adenine dinucleotide rescues the phenotype of frataxin
deficiency.
Gonzalez-Cabo P, Ros S, Palau F.
Laboratory of Genetics and Molecular Medicine, Instituto de
Biomedicina de Valencia, CSIC, Valencia, Spain.
Abstract
BACKGROUND: Friedreich ataxia is a neurodegenerative disease
caused by the lack of frataxin, a mitochondrial protein. We
previously demonstrated that frataxin interacts with complex II
subunits of the electronic transport chain (ETC) and putative
electronic transfer flavoproteins, suggesting that frataxin
could participate in the oxidative phosphorylation. METHODS AND
FINDINGS: Here we have investigated the effect of riboflavin and
its cofactors flavin adenine dinucleotide (FAD) and flavin
mononucleotide (FMN) in Saccharomyces cerevisiae and
Caenorhabditis elegans models of frataxin deficiency. We used a
S. cerevisiae strain deleted for the yfh1 gene obtained by
homologous recombination and we assessed growth in fermentable
and non-fermentable cultures supplemented with either riboflavin
or its derivates. Experiments with C. elegans were performed in
transient knock-down worms (frh-1[RNAi]) generated by
microinjection of dsRNA frh-1 into the gonads of young worms. We
observed that FAD rescues the phenotype of both defective
organisms. We show that cell growth and enzymatic activities of
the ETC complexes and ATP production of yfh1Delta cells were
improved by FAD supplementation. Moreover, FAD also improved
lifespan and other physiological parameters in the C. elegans
knock-down model for frataxin. CONCLUSIONS/SIGNIFICANCE: We
propose that rescue of frataxin deficiency by FAD
supplementation could be explained by an improvement in
mitochondrial respiration. We suggest that riboflavin may be
useful in the treatment of Friedreich ataxia.
http://clinicaltrials.gov/ct2/show/NCT00824512
Efficacy of EGb761
in Patients Suffering From Friedreich Ataxia
This study is currently recruiting participants.
Verified by Ipsen, May 2010
First Received: January 15, 2009 Last Updated: May 26, 2010
History of Changes
Sponsor: Ipsen
Information provided by: Ipsen
ClinicalTrials.gov Identifier: NCT00824512
Purpose
The purpose of this protocol is to determine the efficacy of EGb
761 120 mg bid versus placebo in patients suffering from
Friedreich Ataxia
Condition Intervention Phase
Friedreich Ataxia
Drug: EGb 761 120 mg bid
Drug: Placebo 1 tablet BID
Phase II
Study Type: Interventional
Study Design: Allocation: Randomized
Control: Placebo Control
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator,
Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Phase II, Randomised, Double Blind Study
Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in
Patients Suffering From Friedreich Ataxia
Resource links provided by NLM:
Genetics Home Reference related topics: deoxyguanosine kinase
deficiency Friedreich ataxia Marinesco-Sjögren syndrome
mitochondrial neurogastrointestinal encephalopathy disease
MedlinePlus related topics: Exercise and Physical Fitness
Friedreich's Ataxia
Drug Information available for: EGB 761
U.S. FDA Resources
Further study details as provided by Ipsen:
Primary Outcome Measures:
•Creatine rephosphorylation rate (sec-1) post-exercise using
P-31 NMR spectroscopy, calculated with correction according to
muscular pH. [ Time Frame: Assessed at the baseline (W0) and
W12. ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
•Post-exercise skeletal muscle perfusion (ml/min/100 g of tissue)
[ Time Frame: Assessed at the baseline (W0) and W12 ] [
Designated as safety issue: No ]
•Peak post exercise perfusion (ml/mn/100 g of tissue) [ Time
Frame: Assessed at the baseline (W0) and W12 ] [ Designated as
safety issue: No ]
•Adverse events [ Time Frame: Assessed at the baseline (W0) and
W12 ] [ Designated as safety issue: Yes ]
Estimated Enrollment: 20
Study Start Date: June 2008
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data
collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
EGb 761® 120 mg Drug: EGb 761 120 mg bid
EGb 761® 120 mg bid, orally for 12 to 14 weeks
2: Placebo Comparator
Placebo 1 tablet Drug: Placebo 1 tablet BID
Placebo 1 tablet BID, orally for 12 to 14 weeks
Eligibility
Ages Eligible for Study: 12 Years to 22 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:
•Friedreich ataxia diagnosis confirmed by evidenced mutation
expansion of Frataxin gene
•Ambulatory patient, with depressed tendon reflexes and
pyramidal syndrome associated or not to a loss of position or
vibration senses or dysarthria
•Patient able to perform the tests of the study
Exclusion Criteria:
•Severe cardiac disease as assessed by echocardiography
performed at least within 6 months before screening or during
the wash out period (4 weeks)
•Absolute contra-indication to NMR examination: iron and any
magnetic objects implanted in the whole body, e.g. some
neurostimulators, cardiac pace-makers, vascular clips and other
implanted orthopaedic prosthesis
•Patient who did not deplete at baseline PCr pool by more than
30 % during the exercise bout
•Any continuous use of the following forbidden medications:
•other antioxidant such as idebenone, coenzyme Q, vitamin E/C
taken for less than 4 weeks prior study treatment start (ie for
antioxidant drugs a mandatory wash-out period of 4 weeks prior
study drug start has to be observed),
•any other vasodilators
•tranquilizer such as benzodiazepine, meprobamate or buspirone,
and/or antidepressant (only one), at non stable dose
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier:
NCT00824512
Contacts
Contact: Ipsen Recruitment Enquiries clinical.trials@ipsen.com
Locations
France
Hospital Necker Enfants Malades Recruiting
Paris, France, 75015
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Cécile Merdrignac, MD Ipsen
Responsible Party: Ipsen ( Cecile Merdrignac, Medical
Development Director )
ClinicalTrials.gov Identifier: NCT00824512 History of Changes
Other Study ID Numbers: 2-39-00240-133
Study First Received: January 15, 2009
Last Updated: May 26, 2010
Health Authority: France: Afssaps - French Health Products
Safety Agency
ClinicalTrials.gov
processed this record on June 21, 2010
The ORTHOSuperSite is intended for physician use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will the ORTHOSuperSite be used for medical advice to patients.